A naukri.com initiative
Bioengineer
1w
216
Image Credit: Bioengineer
Extend Your Lifespan: New Insights Revealed
- A study from the Max Planck Institute for Biology of Ageing reveals that combining the cancer drugs Rapamycin and Trametinib extends mice lifespan and healthspan significantly.
- Rapamycin, an mTOR inhibitor, slows metabolic activity, reduces cellular senescence, and enhances longevity.
- Trametinib, by inhibiting MEK1 and MEK2 kinases, has geroprotective effects not previously established in mammals until this study.
- The dual therapy of Rapamycin and Trametinib boosted lifespan by around 30 percent in mice due to potential synergistic effects.
- The combination treatment reduced systemic inflammation in aging tissues and delayed the onset of cancers in mice.
- Gene expression analysis revealed unique transcriptional changes from the dual therapy affecting lifespan regulation pathways.
- This study emphasizes the potential of rational polypharmacy to amplify health and longevity benefits safely.
- The researchers highlight the aim to extend healthy life duration and delay chronic diseases rather than merely increasing total lifespan.
- By targeting aging processes systemically, interventions like this may reshape preventive medicine and geriatric care substantially.
- The study's findings encourage clinical translation of the therapy to enhance life quality and length in humans.
Read Full Article
13 Likes
For uninterrupted reading, download the app